Clinical Controversies: Management of the Axilla—
Giacomo Montagna, Lori Pierce, and Sherry Shen will address this topic in a special session at #SABCS25 (December 9-12). Learn more:
buff.ly/ykgbF15
@sherryshenmd.bsky.social
A big thank you to Dr. Mouabbi @jamouabbi.bsky.social
and Dr. Shen @sherryshenmd.bsky.social for your time and wonderful presentations on lobular cancer. Thank you
@graspcancer.bsky.social for organizing these sessions!
So great meeting you! Let’s connect again soon :)
Thank you @theaacr.bsky.social for inviting me to speak on integrating GLP-1RAs into clinical cancer care. Great session alongside Drs. Stephen Hursting & Rong Xu. Some data on use in cancer patients now, but so much more needed!
At #AACR25, join breast medical oncologist @sherryshenmd.bsky.social for an education session on best practices to introduce GLP1-RAs, like Ozempic, into clinical #cancer care. @mskcancercenter.bsky.social @theaacr.bsky.social Learn more: bit.ly/4jso7Ed
3:01-3:21 p.m. CT
Congrats!
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Thanks Sarah! While we didn’t compare lobular vs. ductal, mPFS in our cohort was similar to other real-world cohorts of predominantly IDC patients.
When @breastcancerdoc.bsky.social & I are unintentionally matching at our poster on T-DXd in pts with HER2-low lobular MBC. PFS 7.2m in total cohort, shorter in those with PIK3CA/AKT/PTEN muts & trend toward longer in HER2mut. More research needed in lobular BC!
First Bluesky post! EMBER-3 presented by my mentor @breastcancerdoc.bsky.social demonstrating greater mPFS as single agent vs. SOC ET in ESR1mut, and impressive benefit of imlunestrant+abema with mPFS 9.4 months, 59% had prior CDK4/6i. Novel ET + CDK4/6i switch is intriguing - ELAINE3 is enrolling!
